News Releases Year: All News201920182017201620152014 Items per page All News2550 Summary ToggleContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study Summary Toggle May 30, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present at 2018 BIO International Convention Summary Toggle May 29, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split Summary Toggle May 24, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™ Summary Toggle April 12, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board Summary Toggle April 9, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress™ Summary Toggle April 3, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population Summary Toggle February 22, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018 Summary Toggle February 21, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway Summary Toggle February 12, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference Summary Toggle February 9, 2018 View News Release > Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
